PBYI
PUMA BIOTECHNOLOGY, INC.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Feb 26 Puma Biotechnology reported fourth quarter and full year 2025 financ…
- S Jun 12 5 insiders sell $572.7K at $7.20
- S Jul 6 3 insiders sell $511.5K at $8.26
- S Sep 14 2 insiders sell $612.5K at $9.12
Signal stack
Where each data set points today.
- InsidersBEARISH
9 insiders sold $1.7M.
- InstitutionsBULLISH
Q2 2026: 13 added (0 new), 7 trimmed or exited.
- AnalystsBEARISH
0 of 6 rate it Buy or better. Price is above every target.
- TrendUPTREND
12% above its 50-day average. New closing high $11.26 on Oct 22.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $10.9M |
| MILLENNIUM MANAGEMENT LLC | TRIM | $4.9M |
| MORGAN STANLEY | TRIM | $2.2M |
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | $596.1K |
| Vanguard Global Advisers, LLC | ADD | $375.2K |
| DEUTSCHE BANK AG\ | ADD | $350.3K |
| WELLS FARGO & COMPANY/MN | DOUBLED | $305.0K |
| Creative Planning | ADD | $289.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
6 analystsPrice is above the highest target. Median implies −45%.Targets as of Aug 15, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 7, 2026 | TD Cowen MAINTAIN | Hold |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 14, 2026 | Cesano Alessandra Director | EXERCISE | $146.5K |
| Sep 14, 2026 | Cesano Alessandra Director | SELL | $567.0K |
| Sep 14, 2026 | WILSON TROY EDWARD Director | SELL | $45.5K |
| Jul 6, 2026 | AUERBACH ALAN H President and CEO | SELL | $364.1K |
| Jul 6, 2026 | NOUGUES MAXIMO F Chief Financial Officer | SELL | $77.6K |
| Jul 6, 2026 | HUNT DOUGLAS M See Remarks | SELL | $69.9K |
| Jun 12, 2026 | Dorval Allison Director | SELL | $83.6K |
| Jun 12, 2026 | MOYES JAY M Director | SELL | $158.8K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
7 filings · 0 bullish · 1 bearish · 1 mixed · 5 neutral- NEUTRAL SC 13D/AOct 6, 2026
Alan H. Auerbach, CEO and President of Puma Biotechnology, filed an amended Schedule 13D reporting…
The warrant expiration removes a potential overhang of ~4.1% dilution at the $16 strike, which is now moot. Monitor for any insider selling or open-market purchases by Auerbach in the coming weeks…
- BEARISH CLUSTERSep 16, 2026
Two directors at Puma Biotechnology sold a combined $612K in open-market shares over a one-week…
The absence of C-suite selling and the modest dollar amount limit the bearish signal, but the cluster of two directors selling without a 10b5-1 plan suggests potential caution ahead of upcoming data…
- NEUTRAL CLUSTERJul 8, 2026
Two PBYI insiders, including the CFO, sold a combined $147K in open-market sales over a 7-day…
The insider sales are too small to convey a bearish signal. Monitor for larger insider transactions or changes in corporate events (e.g., earnings, pipeline updates) that could drive material moves.
- NEUTRAL 144Jul 6, 2026
CEO Alan Auerbach files Form 144 to sell 44,058 shares, currently worth approximately $364K, to…
This is a standard sell-to-cover for tax obligations on restricted stock vesting — not a bearish signal. The CEO remains a director and officer with a large continuing stake. No follow-through…
All PBYI filing & press-release reports (7)
- SC 13D/A reportOct 6, 2026
- CLUSTER reportSep 16, 2026
- CLUSTER reportJul 8, 2026
- 144 reportJul 6, 2026
- CLUSTER reportJun 15, 2026
- 144 reportJun 12, 2026
- 8-K reportFeb 26, 2026